EGFR

Overview

EGFR, the epidermal growth factor receptor, is a transmembrane receptor tyrosine kinase encoded by the EGFR gene. It belongs to the ERBB family of receptors and is activated by ligands such as epidermal growth factor. Upon activation, EGFR triggers intracellular signaling cascades including the PI3K/AKT/mTOR, JAK2/STAT3, and MAPK pathways, which regulate cell proliferation, survival, migration, differentiation, and tissue repair. Because of this central signaling role, EGFR is a major biological regulator in normal physiology and a prominent therapeutic target in oncology.

Clinically, EGFR is best known for its role in EGFR-mutated non-small cell lung cancer (NSCLC), where activating mutations can drive tumor growth and confer sensitivity to EGFR-targeted tyrosine kinase inhibitors (TKIs). EGFR signaling is also implicated in resistance biology, including bypass signaling through MET, interactions with HER2, and receptor stabilization mechanisms involving ubiquitin-dependent degradation. Beyond cancer, EGFR-associated signaling has also been studied in tissue regeneration and wound repair.

Focus of Latest Publications

Recent studies centered on EGFR largely reflect its continued importance as a therapeutic target in EGFR-mutated NSCLC and as a signaling node in resistance and combination-treatment strategies.

Several publications examined EGFR-TKIs across different generations in advanced EGFR-mutated NSCLC. A real-world study compared first- and third-generation EGFR-TKIs for advanced disease, reflecting ongoing evaluation of treatment sequencing and effectiveness in routine practice. Another observational study reported on afatinib 30 mg daily in patients with advanced NSCLC harboring common EGFR mutations, reinforcing afatinib’s role as an approved first-line option for sensitizing EGFR mutations. A phase III trial, AENEAS2, evaluated aumolertinib with or without chemotherapy in advanced EGFR-mutated NSCLC, noting that third-generation EGFR-TKIs are standard first-line therapies but that resistance and progression remain major limitations.

Resistance biology was a major theme. One real-world study of vebreltinib plus EGFR-TKI in EGFR-mutated NSCLC with MET-driven resistance highlighted MET amplification/overexpression as a key bypass mechanism of resistance to EGFR-TKIs. Another study on acquired TKI resistance in murine RET+ lung adenocarcinoma found that resistant tumors and derived cell lines showed sensitivity to MET- and ERBB-targeted TKIs, indicating bypass signaling through receptor tyrosine kinases. These findings align with broader evidence that EGFR-targeted therapy often requires combination strategies when tumors activate alternative signaling routes such as EGFR-MET or other ERBB-family pathways.

EGFR also appeared in studies of metastatic disease management. A multicenter propensity-matched analysis assessed the clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC, including approaches such as (chemo)radiotherapy and consolidative surgery. In a separate case-based report, osimertinib re-escalation with filgrastim support was used to rescue a suprasellar metastasis in EGFR-mutant NSCLC, underscoring the challenge of maintaining adequate EGFR-TKI exposure in lung cancer brain metastases and other CNS sites when toxicity limits dosing.

Beyond lung cancer, EGFR was implicated in additional mechanistic and translational studies. In hepatocellular carcinoma, ACSS2-driven palmitate biosynthesis was reported to facilitate EGFR palmitoylation, protecting the receptor from ubiquitin-dependent degradation and contributing to lenvatinib resistance. In esophageal squamous cell carcinoma cells, epigallocatechin gallate (EGCG) attenuated arecoline-induced migration and invasion through EGFR/AKT/P38 signaling, suggesting a role for EGFR-linked pathways in metastasis-related phenotypes. In HER2-related resistance biology, one study reported that EGFR inhibition restored trastuzumab sensitivity, supporting cross-talk between EGFR and HER2-directed therapy responses.

EGFR signaling was also connected to tissue regeneration and biomaterial-based repair. A dual-enzyme cascade protein hydrogel membrane study found that a biomaterials-based system activated EGFR-associated signaling pathways (PI3K/AKT/mTOR) and improved diabetic wound repair, indicating that EGFR can be leveraged outside oncology to promote regeneration and restore dermal architecture. Collectively, these studies reinforce EGFR as a central signaling hub in cancer progression, drug resistance, and tissue repair.

Key Publications

• NEWFeb Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study. (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2025, PMID 39962869): "Different generations of EGFR-tyrosine kinase inhibitors (TKIs) are available to treat EGFR-mutated NSCLC."
• NEWApr 3-Deoxy-4-sulfonamido-butein derivatives promote cell cycle arrest and apoptosis by inhibiting EGFR/JAK2/STAT3 signaling in A549 lung cancer cells. (Bioorganic & medicinal chemistry, 2026, PMID 42044554): "these lead candidates operated through a convergent dual-targeting mechanism by directly inhibiting epidermal growth factor receptor (EGFR) tyrosine kinase activity while concurrently suppressing the downstream JAK2/STAT3 signaling axis."
• NEWJul Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients. (Lung cancer (Amsterdam, Netherlands), 2026, PMID 42068890): "MET amplification/overexpression is a key resistance mechanism to EGFR-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC)."
• Jul Clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC: A propensity-matched multicenter analysis. (Lung cancer (Amsterdam, Netherlands), 2026, PMID 42068892): "...in patients with advanced or metastatic epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)..."
• Jul ACSS2 drives Lenvatinib resistance in hepatocellular carcinoma through palmitoylation. (Pharmacological research, 2026, PMID 42134048): "Mechanistically, ACSS2-driven palmitate biosynthesis facilitates EGFR palmitoylation, which shields the receptor from ubiquitin-dependent degradation."
• Jul Rare EGFRm NSCLC: More First-Line Options Emerge. (Cancer discovery, 2026, PMID 42224429): "Findings from the phase III WU-KONG28 trial indicate that the next-generation tyrosine kinase inhibitor sunvozertinib, an approved later-line option for patients with non-small cell lung cancer harboring EGFR exon 20 insertions, also looks effective up front, besting chemotherapy."
• Jul Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. (The Lancet. Oncology, 2026, PMID 42296979): "Although third-generation epidermal growth-factor receptor (EGFR)-tyrosine-kinase inhibitors (TKIs) are standard first-line therapies for patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC), their effectiveness is often limited by the emergence of drug resistance and subsequent disease progression."
• Jul Epigallocatechin Gallate Attenuates Arecoline-induced Migration and Invasion in Esophageal Squamous Cell Carcinoma Cells Associated With EGFR/AKT/P38 Signaling. (Anticancer research, 2026, PMID 42373249): "Epigallocatechin gallate (EGCG), a major polyphenol in green tea, has exhibited anti-cancer and anti-metastatic activity in multiple tumor models."
• Jul An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. (Thoracic cancer, 2026, PMID 42381340): "Afatinib is an approved first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations."
• Jan Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. (In vivo (Athens, Greece), 2026, PMID 42379747): "Managing central nervous system (CNS) metastases of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer can be challenging if dose-limiting toxicities prevent adequate drug exposure."